temozolomida ratiopharm 100 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
temozolomida ratiopharm 140 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
temozolomida ratiopharm 180 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
temozolomida ratiopharm 20 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
temozolomida ratiopharm 250 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
temozolomida ratiopharm 5 mg capsulas duras efg
ratiopharm españa, s.a. - temozolomida - excipientes: lactosa anhidra,carboximetilalmidon sodico - agentes alquilantes - otros agentes alquilantes - temozolomida
erivedge
roche registration gmbh - vismodegib - carcinoma, célula basal - agentes antineoplásicos - erivedge está indicado para el tratamiento de pacientes adultos con:- sintomático metastásico de células basales y el carcinoma localmente avanzado de carcinoma de células basales inapropiado para la cirugía o la radioterapia.
lonsurf
les laboratoires servier - trifluridine, tipiracil clorhidrato de - neoplasias colorrectales - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
neparvis
novartis europharm limited - sacubitril, valsartan - insuficiencia cardíaca - agentes que actúan sobre el sistema renina-angiotensina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
odomzo
sun pharmaceutical industries europe b.v. - difosfato de sonidegib - carcinoma, célula basal - agentes antineoplásicos - odomzo está indicado para el tratamiento de pacientes adultos con carcinoma localmente avanzado de la célula básica (bcc) que no son susceptibles de tratamiento curativo de la cirugía o la radioterapia.